Clinical Trial ProgressThe company activated roughly 50 sites for the ALPHA3 trial, indicating robust progress in its clinical trial efforts.
Regulatory MilestonesThe FDA agreed to a single-arm study in relapsed/refractory patients, which is a significant regulatory milestone.
Safety And EfficacyEncouraging MRD conversion rate and safety profile with FC regimen seen with early, unplanned review of data.